hagemans, Iris.jpg
Ms. Iris Hagemans 

PhD Candidate

Cancer development and immune defense


Recently, a new type of treatment has become available, which blocks immunosuppressive signals generated by tumor cells. Breakthroughs in the field of these checkpoint inhibitors have even been called the scientific breakthrough of the year 2013. However, the systemic character of this type of therapy has a significant drawback: it elicits auto-immune reactions. The goal of the current project is to generate optimized molecular immune checkpoint-inhibitory approaches.

<< go back